SUGAMMADEX

Other

Brand names: BRIDION

Intravenous

Mechanism of Action

12.1 Mechanism of Action BRIDION is a modified gamma cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium.

Indications

See full prescribing information

Contraindications

• anaphylaxis
• anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex [see Warnings and Precautions (5.1)
• Adverse Reactions (6) ] . Known hypersensitivity to sugammadex or any of its components. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Anaphylaxis : Be prepared for hypersensitivity reactions (including anaphylactic reactions) and take necessary precautions
Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with BRIDION
4 Risk of Prolonged Neuromuscular Blockade In clinical trials, a small number of patients experienced a delayed or minimal response to the administration of BRIDION [see Clinical Studies (14
7 Risk of Recurrence of Neuromuscular Blockade Due to Displacement Interactions Recurrence of neuromuscular blockade may occur due to displacement of rocuronium or vecuronium from BRIDION by other drugs [see Drug Interactions (7

Known Side Effects

3 documented side effects by frequency

Low Blood Pressure

1-10%

Drug Not Working

1-10%

Shortness of Breath

0.1-1%

Community Discussions

No community discussions found for SUGAMMADEX yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous